Trajan Group Holdings (ASX:TRJ): FY26 Margin Recovery and Cash Management

Aditi Sarkar

15 October 2026 06:05 PM AEDT

Trajan Group Holdings (ASX:TRJ): FY26 Margin Recovery and Cash Management

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Trajan reported FY26 group Revenue of $161.4M and normalised EBITDA of $13.2M.
Second-half normalised EBITDA reached $8.1M, compared with $5.0M in the first half.
Second-half proforma gross Margin increased to 40.6% from 37.4% in the first half.
Year-end cash was $12.6M, while FY26 Capital Expenditure totalled $3.4M.
Operational priorities include inventory optimisation, cash conversion and Debt reduction.

Trajan Group Holdings Limited (ASX:TRJ) designs and manufactures analytical and life sciences products, including precision consumables, components and devices used to test biological, food, water and environmental samples. Its FY26 results, released on 27 August 2026, reflected weaker full-year Earnings alongside an improvement in second-half profitability. Manufacturing efficiency, currency movements and the management of Working Capital featured prominently in the company’s disclosures.

Full-Year Results and Second-Half Progress

For FY26, Trajan (ASX:TRJ) reported group revenue of $161.4M and normalised earnings before interest, tax, Depreciation and Amortisation (nEBITDA) of $13.2M. These figures are measures of the company’s activity and underlying operating earnings; they are not measures of cash generated. The distinction matters because inventory, customer payments, capital spending and debt servicing can affect Liquidity independently of reported profitability.

The year contained two contrasting operating periods. H2 FY26 nEBITDA increased to $8.1M, compared with $5.0M in H1 FY26, a 61.8% improvement. Proforma gross margin rose from 37.4% in the first half to 40.6% in the second half. These developments indicate that operational changes affected the company’s second-half cost structure, although the full-year figures still reflected earlier pressures.

How Efficiency Measures Affected Margins

Trajan (ASX:TRJ) identified several initiatives behind the second-half margin improvement. Its Project Neptune programme included adjustments to staffing, facilities and manufacturing processes. The company disclosed a $1.2M second-half benefit from Project Neptune headcount and facilities measures and a further $1.2M benefit from reductions in Corporate Services headcount. It also reported continued automation, additional operational transfers to Malaysia and progress on a global enterprise resource planning rollout.

Such measures influence profitability through production efficiency and operating expenses rather than automatically generating equivalent cash savings. For a manufacturer, the timing of inventory purchases, payments to suppliers and collections from customers remains important when interpreting operating performance. ASX:TRJ therefore presents a useful example of why margin improvement and cash conversion require separate consideration.

Currency, Cash and Working Capital

Foreign exchange movements were a material feature of the FY26 result. Trajan estimated that Australian dollar appreciation affected second-half reported revenue by approximately $5.0M and nEBITDA by $2.4M. On a currency-adjusted basis, the company indicated that H2 nEBITDA would have been $10.5M, rather than the reported $8.1M. This adjustment helps explain the currency effect but does not replace the statutory or reported earnings figures.

Trajan (ASX:TRJ) disclosed year-end cash of $12.6M and FY26 capital expenditure of $3.4M. The group specifically identified inventory optimisation, improved cash conversion, disciplined capital allocation and debt reduction as priorities following its FY26 result.

Demand and Execution Factors

The FY26 announcement described Components and Consumables as resilient, while Capital Equipment faced weakness in North America linked to funding conditions and in global food markets. Trajan also reported an order book of $8.7M at 30 June 2026. An order book indicates recorded Demand at a point in time, not necessarily the timing of revenue recognition or customer cash receipts.

Key Insights

Trajan (ASX:TRJ) ended FY26 with higher second-half margins and nEBITDA than in the first half, despite lower full-year financial outcomes and currency translation pressure. Its $12.6M year-end cash position and stated focus on inventory, debt and cash conversion provide a framework for understanding the link between operating improvements and balance-sheet management. The company’s analytical product portfolio is supported by specialised manufacturing, making execution costs and the conversion of earnings into cash important measures of performance.

FAQs

Q: What does Trajan Group Holdings produce?

A:It manufactures analytical and life sciences products used in testing biological, food and environmental samples.

Q: What revenue did Trajan report for FY26?

A:The company reported FY26 group revenue of $161.4M.

Q: How did profitability change in H2 FY26?

A:Normalised EBITDA was $8.1M in H2 FY26 versus $5.0M in H1 FY26.

Q: What was the FY26 closing cash balance?

A:Trajan reported $12.6M in cash at year-end.

Q: Why is working capital relevant to Trajan?

A:Inventory, receivables and payment timing influence how operating earnings translate into available cash.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.